{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-080765","form_type":"8-K","ticker":null,"cik":"0001971543","company_name":"Mural Oncology plc","filed_at":"2025-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.600683+00:00","generated_at":"2026-05-23T15:04:58.028862+00:00","sec_items":["2.05","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mural Oncology ends nemvaleukin alfa development, cuts 90% of staff","bullets":["Discontinues all clinical development of nemvaleukin alfa after phase 2 ARTISTRY-6 and phase 3 ARTISTRY-7 trial data.","Workforce reduction of approximately 104 positions, or about 90%, expected to complete by end of Q2 2025.","Estimated costs of $9.0-$10.0 million in severance and benefits, plus $2.0-$4.0 million in non-cash impairment charges.","Engages Lucid Capital Markets to explore strategic alternatives focused on maximizing shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-080765","json":"https://secwatch.observer/filing/0001193125-25-080765.json","markdown":"https://secwatch.observer/filing/0001193125-25-080765.md","text":"https://secwatch.observer/filing/0001193125-25-080765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525080765/0001193125-25-080765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525080765/d940480d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:04:58.028862+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78178295387d4f3b02901950f7e4fa9f6b4d20b1","claim":"Mural Oncology plc announced a restructuring with charges of approximately $9.0 million to $10.0 million (approximately 104 positions, or approximately 90%).","evidence_excerpt":"90% (the “Reduction”). The Company expects to substantially complete the Reduction by the end of the second quarter of 2025. The Company expects to incur costs of approximately $9.0 million to $10.0 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. Additionally, the Company expects to incur $2.0 million to $4.0","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525080765/0001193125-25-080765-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $9.0 million to $10.0 million"},{"label":"Headcount","value":"approximately 104 positions, or approximately 90%"}],"fact_type":"restructuring_charge"},{"claim_id":"d5bdc49eea3800981ff9f13443fe0f806552e9c1","claim":"Mural Oncology plc announced a impairment with charges of $2.0 million to $4.0 million affecting property and equipment.","evidence_excerpt":"Additionally, the Company expects to incur $2.0 million to $4.0 million in non-cash impairment charges associated with property and equipment expected to be sold or otherwise disposed of.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971543/000119312525080765/0001193125-25-080765-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"impairment"},{"label":"Charge","value":"$2.0 million to $4.0 million"},{"label":"Affected area","value":"property and equipment"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}